INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Article

Comprehensive Review on Amoxiclav in Different Clinical Condition

J. S. Venkatesh, Ramya G. S.*, Supin P. Sabu, Sumaya S.

S. C. S. College of Pharmacy, Harapanahalli.

ARTICLE INFO

Published: 8 Dec 2025
Keywords:
Co-amoxiclav, Amoxicillin/clavulanate, β-lactamase, Clostridium difficile.
DOI:
10.5281/zenodo.17857325

ABSTRACT

Amoxicillin/clavulanate (co-amoxiclav) is a commonly used antibiotic in community healthcare. It combines amoxicillin and clavulanate potassium to fight β-lactamase-producing bacteria. This combination has been around since the 1970s. Even though it has the same half-life, it is protein-bound and heat unstable. Amoxicillin helps block cell wall synthesis, while clavulanate permanently binds to and deactivates the beta-lactamase enzymes made by resistant bacteria. Despite the many newer antibiotics developed in recent decades, amoxicillin, either alone or with clavulanic acid, remains one of the most used antibacterials. Even though they are often referred to as 'twin drugs', they differ in antibacterial activity and safety. They can cause gastrointestinal side effects, including Clostridium difficile infection, which limits the oral doses of amoxicillin in combination.

INTRODUCTION

Infections are still a common cause of illness and death around the world. Acute respiratory tract infections (RTIs) are one of the main reasons for hospital admissions and increased costs for national health systems. The first β-lactams, penicillin G and V, were licensed in the 1950s. They had significant drawbacks, but in the 1960s, a semisynthetic process was developed to produce newer penicillin's that greatly improved their effectiveness. Ampicillin and amoxicillin (AMX) were the two key developments. They were effective not just for upper and lower RTIs, but also for urinary tract infections, soft-tissue infections, and skin infections. In the 1970s, combining the broad-spectrum antibiotic amoxicillin with the β-lactam inhibitor clavulanic acid provided a strong solution to the growing issues of penicillin resistance and mixed infections.

- Molecular Formula: **C24H28N4O10S**
- Molecular weight: 564.6 g/mol
- Monoisotopic mass: 564.15261428
- Bactericidal/ static: Bactericidal
- Spectrum of activity: Broad

***Corresponding Author:** Ramya G. S.
Address: *S. C. S. College of Pharmacy, Harapanahalli..*
Email : ramyags06072001@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

MECHANISM OF ACTION

Amoxicillin acts by inhibiting the biosynthesis of the peptidoglycan layer in bacterial cell walls it maintains the structural integrity of the cell. Amoxicillin binds to these penicillin-binding protein (PBP). PBPs, impeding peptidoglycan synthesis and disrupting cell wall construction, ultimately leading to bacterial destruction.

Clavulanic acid functions by thwarting bacterial degradation of beta-lactams. Over time, certain bacteria have developed resistance to standard beta-lactam antimicrobials. Clavulanic acid counteracts this resistance mechanism by binding to and deactivating beta-lactamases, thereby reinstating the antimicrobial efficacy of amoxicillin

SPECTRUM OF ACTIVITY:

Clavulanic acid has only weak antibacterial activity against most species, but the addition of clavulanic acid to amoxycillin increases the susceptibility to amoxycillin of amoxycillin-resistant Staphylococcus aureus, many Enterobacteriaceae, amoxycillin-resistant Hemophilus influenzae and Neisseria gonorrhoeae and Bacteroides fragilis. The inhibitory concentration of amoxycillin usually decreases with increasing concentrations of clavulanic acid. Strains of bacteria sensitive to amoxycillin are no more susceptible to amoxycillin/clavulanic acid than to the antibiotic alone.

PHARMACOKINETICS

Absorption: Clavulanate potassium absorption is increased when taken with food.

Distribution: Amoxicillin is approximately 18% bound to serum proteins, and clavulanic acid is about 25% bound. Amoxicillin diffuses readily into most body tissues and fluids, except the brain and spinal fluid. Amoxicillin and clavulanic acid have been detected in middle ear effusions.

Metabolism: Amoxicillin is primarily eliminated unchanged in the urine. Between 50% and 85% of the oral dose is eliminated within 6 hours. In contrast, clavulanate is metabolized considerably, and between 25% and 40% of the drug is excreted unchanged in the urine.

Elimination: After oral administration of amoxicillin and clavulanate potassium, the approximate half-life is 1.3 hours for amoxicillin and 1 hour for clavulanic acid.

INDICATION

FDA-approved Indications:

- community-acquired pneumonia
- Aspiration pneumonia
- acute bacterial rhinosinusitis
- urinary tract infections
- acute otitis media, skin and soft tissue infections.

Off-label Uses:

Treatment of human or animal bite wounds, group A streptococcal infections, impetigo, acute exacerbations of chronic obstructive pulmonary disease and bronchiectasis, diabetic foot infections, odontogenic infections peritonsillar cellulitis/abscess, helicobacter pylori eradication, acute bacterial sinusitis, periodontitis, actinomycosis.

DOSAGE AND ADMINISTRATION

The usual dosage for routine oral use in adult infections is 250/125mg or 500/125mg 3 times daily, although in Italy the usual dose is 875/125mg twice or 3 times daily, depending on the severity of infection. The recommended daily

dose in children is 20 to 40mg/ kg, based on the amoxicillin component. Dosage reductions are necessary in patients with renal failure. Amoxicillin/clavulanic acid should be administered with food and is contraindicated in patients with a known history of β-lactam hypersensitivity.

STEWARDSHIP CONSIDERATIONS

1. Prefer amoxicillin alone when β-lactamase production is unlikely.
2. Use the lowest effective clavulanate dose and shortest effective duration.
3. Reserve high-exposure regimens for indications with demonstrated benefit (e.g., severe/confirmed β-lactamase infections).
4. Follow local susceptibility data and guidelines to avoid unnecessary broadening of empiric therapy

ADVERSE EFFECTS

- Gastrointestinal (Most Common): Diarrhea (the most frequent adverse event), nausea, vomiting, and abdominal discomfort. Taking the medication with food can help mitigate these effects.

- Hepatotoxicity (Rare but Significant): It is one of the leading causes of idiosyncratic drug-induced liver injury (DILI), often presenting as cholestatic jaundice. This is typically reversible upon drug discontinuation. But can be serious. Risk factors include advanced age and male sex.

- Hypersensitivity: Allergic reactions are possible, ranging from rash to severe anaphylaxis (due to the amoxicillin component).

- Clostridium difficile Infection: As with any broad-spectrum antibiotic, it carries a risk of Clostridium difficile-associated diarrhea (CDAD)

FUTURE DIRECTIONS

Research continues into optimized dosing (pharmacodynamic targets), novel β-lactamase inhibitors, combination formulations (e.g., add-on agents or adjuvants), and strategies to minimize adverse effects such as hepatotoxicity while preserving efficacy. Surveillance and randomized data comparing amoxicillin vs amoxicillin-clavulanate in many indications will further refine appropriate use**.**

CONCLUSION

Clavulanic acid and amoxicillin have a similar half-life of about one hour. They are widely distributed in body tissues and fluids, including the liver, lungs, prostate, muscles, and synovial fluid, with low plasma protein binding. The pharmacodynamics of co-amoxiclav highlight its efficacy in inhibiting bacterial cell wall synthesis and overcoming beta-lactamase-mediated resistance. The dosing regimen has been refined to maximize efficacy and minimize adverse effects, and the twice-daily dosage has been adopted for convenience and compliance. This ratio aims to amplify antimicrobial potency, addressing more severe infections and resistant strains. As clinicians navigate the complexities of infectious diseases, the insights from this review offer guidance on evidence-based decision-making and optimizing patient outcome.

REFERENCES

1. Jena D, Ghosh TK, Pal A, Pawar D, Sharma A. Exploring the Therapeutic Potential of High Dose Co-amoxiclav (1 gm) in Different

Clinical Conditions: A Review. Cureus. 2024 Jul 17;16(7).
2. Jeet K, Kumar S, Singh G, Jaswal R, Kumar D, Thakur A. A Comprehensive Review on Amoxicilin and Clavulanic Acid as Potential Antibacterial Agent. Asian Journal of Pharmaceutical Research and Development. 2022 Aug 14;10(4):108-14.
3. Salvo F, De Sarro A, Caputi AP, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert opinion on drug safety. 2009 Jan 1;8(1):111-8
4. Polaino Moreno V, Caballero-Bermejo AF, Artés Caselles M, Serrano González J, Remírez Arriaga X, González Alcolea N, Equisoain Azcona A, Iglesias García E, Lucena de la Poza JL, Sánchez Movilla A, Ruiz-Antorán B. Efficacy of amoxicillin/clavulanic acid after surgical drainage of perianal abscess in the prevention of the development of anal fistula (PERIQxA study): study protocol for a multicenter randomized, double-blind clinical trial. Trials. 2024 Feb 15;25(1):122.
5. Comprehensive Review of Amoxicillin-Clavulanate: Indications, Administration, and Adverse Effects Mudi Daupadi
6. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs. 1981 Nov;22(5):337-62.
7. Amoxicillin Clavulanate justin Evans; Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990 Feb;39(2):264-307.
8. Ziccardi SR, Groome S, Rebollido Z. Side effects of beta-lactams and tetracyclines. InSide Effects of Drugs Annual 2023 Jan 1 (Vol. 45, pp. 237-247). Elsevier.
9. Hsu H, Siwiec RM. StatPearls [Internet] StatPearls Publishing. Treasure Island, FL. 2022.
10. Sahana S, Kumar R, Nag S, Paul R, Chatterjee I, Guha N. A Review on Alzheimer Disease and Future Prospects. Sahana et al World Journal of Pharmacy and Pharmaceutical Sciences [Internet]. 2020 Jul 11;9(9):1276-85.

HOW TO CITE: J. S. Venkatesh, Ramya G. S., Supin P. Sabu, Sumaya S., Comprehensive Review on Amoxiclav in Different Clinical Condition, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 12, 1479-1482. https://doi.org/10.5281/zenodo.17857325